The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Open accessAbstract
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients. METHODS: We invited patients who had participated in clinical trials in which they received recent or long-term treatment with natalizumab for multiple sclerosis, Crohn's disease, or rheumatoid arthritis to participate. The clinical history, physical examination, brain magnetic resonance imaging (MRI), and testing of cerebrospinal fluid for JC virus DNA were used by an expert panel to evaluate patients for PML. We estimated the risk of PML in patients who completed at least a clinical examination for PML or had an MRI. RESULTS: Of 3417 patients who had recently received natalizumab while participating in clinical trials, 3116 (91 percent) who were exposed to a mean of 17.9 monthly doses underwent evaluation for PML. Of these, 44 patients were referred to the expert panel because of clinical findings of possible PML, abnormalities on MRI, or a high plasma viral load of JC virus. No patient had detectable JC virus DNA in the cerebrospinal fluid. PML was ruled out in 43 of the 44 patients, but it could not be ruled out in one patient who had multiple sclerosis and progression of neurologic disease because data on cerebrospinal fluid testing and follow-up MRI were not available. Only the three previously reported cases of PML were confirmed (1.0 per 1000 treated patients; 95 percent confidence interval, 0.2 to 2.8 per 1000). CONCLUSIONS: A detailed review of possible cases of PML in patients exposed to natalizumab found no new cases and suggested a risk of PML of roughly 1 in 1000 patients treated with natalizumab for a mean of 17.9 months. The risk associated with longer treatment is not known.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Self-citationKleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Progressive Multifocal Leukoencephalopathy
Richardson, E. P. (1961) · New England Journal of Medicine · doi:10.1056/nejm196110262651701 · Cited by 611
Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale
Rice, G. P. A., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 305
Focal white-matter lesions in brain of patients with inflammatory bowel disease
Andus, T., Roth, M., Kullmann, F., Caesar, I., Gross, V., Feuerbach, S., Schölmerich, J., Geißler, A., & Held, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90013-6 · Cited by 126
Natalizumab and Progressive Multifocal Leukoencephalopathy
Adelman, B., Sandrock, A. W., & Panzara, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmc055235 · Cited by 82
Cited by
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Self-citationRisk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
Egli, A., Infanti, L., Dumoulin, A., Buser, A., Samaridis, J., Stebler, C., Gosert, R., & Hirsch, H. H. (2009) · The Journal of Infectious Diseases · doi:10.1086/597126 · Cited by 781
Tan, C. S., & Koralnik, I. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70040-5 · Cited by 776
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Clifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Self-citationNatalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Nylander, A., & Hafler, D. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58649 · Cited by 495
Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., & Bennett, C. L. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70161-5 · Cited by 447
Self-citationProgressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Self-citationNatalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Self-citationImmune interventions in stroke
Fu, Y., Liu, Q., Anrather, J., & Shi, F.-D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.144 · Cited by 383
Biological Therapies for Inflammatory Bowel Diseases
Rutgeerts, P., Vermeire, S., & Van Assche, G. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.001 · Cited by 363
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Biologic agents for IBD: practical insights
Danese, S., Vuitton, L., & Peyrin-Biroulet, L. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.135 · Cited by 342
Multiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 338
The anatomy and immunology of vasculature in the central nervous system
Mastorakos, P., & McGavern, D. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav0492 · Cited by 333
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
New therapies for inflammatory bowel disease: from the bench to the bedside
Danese, S. (2012) · Gut · doi:10.1136/gutjnl-2011-300904 · Cited by 308
The role of polyomaviruses in human disease
Jiang, M., Abend, J. R., Johnson, S. F., & Imperiale, M. J. (2009) · Virology · doi:10.1016/j.virol.2008.09.027 · Cited by 293
Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Gorfu, G., Rivera-Nieves, J., & Ley, K. (2009) · Current Molecular Medicine · doi:10.2174/156652409789105525 · Cited by 292
Interleukin-1β Induces Blood–Brain Barrier Disruption by Downregulating Sonic Hedgehog in Astrocytes
Wang, Y., Jin, S., Sonobe, Y., Cheng, Y., Horiuchi, H., Parajuli, B., Kawanokuchi, J., Mizuno, T., Takeuchi, H., & Suzumura, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110024 · Cited by 286
“conventional therapies for MS sometimes causes progressive multifocal leukoencephalopathy [41].”
BackgroundTreatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J.-C., Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000341766.59028.9d · Cited by 282
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Clifford, D. B., Ances, B., Costello, C., Rosen-Schmidt, S., Andersson, M., Parks, D., Perry, A., Yerra, R., Schmidt, R., Alvarez, E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.103 · Cited by 278
Self-citationBiology of CCR5 and Its Role in HIV Infection and Treatment
Lederman, M. M., Penn-Nicholson, A., Cho, M., & Mosier, D. (2006) · JAMA · doi:10.1001/jama.296.7.815 · Cited by 266
Vidal, L., Gafter-Gvili, A., Leibovici, L., Dreyling, M., Ghielmini, M., Hsu Schmitz, S.-F., Cohen, A., & Shpilberg, O. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn478 · Cited by 266
Kappos, L., Bates, D., Edan, G., Eraksoy, M., Garcia-Merino, A., Grigoriadis, N., Hartung, H.-P., Havrdová, E., Hillert, J., Hohlfeld, R., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70149-1 · Cited by 262
Self-citationNatalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 253
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Stüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00003.x · Cited by 123
for the MAGNIMS network, Seewann, A., Enzinger, C., Filippi, M., Barkhof, F., Rovira, A., Gass, A., Miller, D., Montalban, X., Thompson, A., et al. (2008) · Journal of Neurology · doi:10.1007/s00415-007-0754-x · Cited by 98
“Therefore, the recognition of this atypical IIDL subtype gains further importance from the reported association of PML with natalizumab treatment [64].”
Self-citationInterferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412
Dayan, C. M., & Wraith, D. C. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03559.x · Cited by 28
Metadata
- Authors
- Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E.-W., Jäger, H. R., & Clifford, D. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-02
- Volume
- 354
- Issue
- 9
- Pages
- 924-933
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159061752
- Cited by
- 790
- References
- 10
- FWCI
- 51.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.